# Study to Assess Sarilumab in Halting Progression of Morphea

> **NCT03679845** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Massachusetts General Hospital**

## Conditions studied

- Morphea, Plaque Form

## Interventions

- **DRUG:** Sarilumab

## Key facts

- **NCT ID:** NCT03679845
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-09-01
- **Primary completion:** 2021-06-30
- **Final completion:** 2021-06-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Difficulty in recruiting patients
- **Last updated:** 2021-09-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03679845

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03679845, "Study to Assess Sarilumab in Halting Progression of Morphea". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03679845. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*